News

PH linked to increased risk of sleep disorders, brain structure changes

Pulmonary hypertension (PH) is associated with an increased risk for sleep disorders, including obstructive sleep apnea, and structural brain changes at the genetic level, according to a recent study. These findings may help “develop new guidelines for the clinical management, personalized diagnosis, and treatment of PH, sleep disorder…

Heart CT scan parameter predicts cardiovascular events in PH

A higher diameter ratio on CT scans between the right ventricle and left ventricle, which are the heart’s lower chambers, independently predicts major adverse cardiovascular events in people with pulmonary hypertension (PH), a study reports. “In our study, the [right ventricle/left ventricle] ratio not only well reflected PH severity,…

MTMR7 protein shows promise as PAH treatment in mice

Boosting the production of a protein called myotubularin-related protein 7 (MTMR7) reversed signs of pulmonary arterial hypertension (PAH) in a mouse model of the disease, a study shows. MTMR7 suppresses the excess growth and migration of cells lining the arteries, which contribute to the narrowing of these blood vessels…

Insulin resistance correlates with disease severity in CTEPH: Study

Insulin resistance or IR — a reduced response of body tissues to insulin, a hormone that regulates blood sugar levels — was found to correlate with disease severity in people with chronic thromboembolic pulmonary hypertension (CTEPH), according to a new study from researchers in China. Further, the team determined that…

Tenax expands development of PH treatment TNX-103

Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The company last year received $100 million in funding to help it complete an ongoing Phase 3 LEVEL trial…

Targeting AURKB enzyme a promising approach in PAH rats

Inhibiting an enzyme known as Aurora kinase B (AURKB) significantly improves multiple measures of blood flow in rat models of pulmonary arterial hypertension (PAH), a study suggests. AURKB blockade worked by suppressing the excessive growth of blood vessel muscle cells, which contributes to the narrowing of pulmonary arteries that…

Pooled trial analysis supports Winrevair as PAH treatment

Winrevair (sotatercept) is generally safe and effective for people with pulmonary arterial hypertension (PAH) when given in addition to their standard of care treatment, a pooled analysis of two clinical trials shows. Along with other benefits, the clinical studies — the Phase 2 PULSAR trial (NCT03496207) and…